Advisor(s)

Dr. John Thurmond, Illinois Mathematics and Science Academy

Location

Room Library

Start Date

26-4-2019 1:40 PM

End Date

26-4-2019 2:04 PM

Abstract

Epidermal Growth Factor Receptor (EGFR) is a transmembrane protein involved in the regulation of signaling pathways and is known to be frequently overexpressed in epithelial tumors. Erlotinib is a small molecule inhibitor of EGFR commonly used for the treatment of lung and pancreatic cancers. In the present study, 707 selective inhibitors of EGFR were designed based on the erlotinib prototype. Results were filtered by parameters outlined in Lipinski’s rule. Molecular simulation programs such as SeeSar, AdmetSar, SwissADME enabled the prediction of the compounds’ toxicity, binding affinity, physicochemical properties, and pharmacokinetics. The equilibrium dissociation constant was decreased from 101.469534 to 0.000054, therefore increasing the binding affinity by over 1,879,065 fold. The data suggested that modifying the 1,2-Dimethoxyethane structures, particularly by replacing oxygens with nitrogens and adding cyclic compounds to the ends, resulted in the greatest increase in binding affinity to EGFR. Rigidifying linkers and adding O-H groups allowed for the decreased inhibition of hERG, a protein involved inducing cardiotoxic effects. These findings may lead to further optimization of anticancer drugs and provide a computational strategy for drug design.

Creative Commons License

Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Share

COinS
 
Apr 26th, 1:40 PM Apr 26th, 2:04 PM

Discovery of EGFR using Erlotinib prototype for the Treatment of Lung and Other Cancers

Room Library

Epidermal Growth Factor Receptor (EGFR) is a transmembrane protein involved in the regulation of signaling pathways and is known to be frequently overexpressed in epithelial tumors. Erlotinib is a small molecule inhibitor of EGFR commonly used for the treatment of lung and pancreatic cancers. In the present study, 707 selective inhibitors of EGFR were designed based on the erlotinib prototype. Results were filtered by parameters outlined in Lipinski’s rule. Molecular simulation programs such as SeeSar, AdmetSar, SwissADME enabled the prediction of the compounds’ toxicity, binding affinity, physicochemical properties, and pharmacokinetics. The equilibrium dissociation constant was decreased from 101.469534 to 0.000054, therefore increasing the binding affinity by over 1,879,065 fold. The data suggested that modifying the 1,2-Dimethoxyethane structures, particularly by replacing oxygens with nitrogens and adding cyclic compounds to the ends, resulted in the greatest increase in binding affinity to EGFR. Rigidifying linkers and adding O-H groups allowed for the decreased inhibition of hERG, a protein involved inducing cardiotoxic effects. These findings may lead to further optimization of anticancer drugs and provide a computational strategy for drug design.

 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.